Archives
|
Entry
|
Blogger
|
Date
▴
|
Xconomist
|
Location
|
|
Illumina Shows its Stuff to Wall Street, Stock Still Slides
|
Luke Timmerman |
11/07/08 |
|
San Diego
|
|
Tysabri’s Roots at the “Hutch,” MediQuest Spurned by FDA, ZymoGenetics Drug Passes Test, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/06/08 |
|
Seattle
|
|
Tysabri: The Big Multiple Sclerosis Drug That Emerged From “The Hutch”
|
Luke Timmerman |
11/04/08 |
|
Seattle
|
|
Democratic Party Fundraiser Dies, After Friends and Family Pushed To Get Him Tysabri
|
Luke Timmerman |
10/31/08 |
|
Boston
|
|
Biogen Idec, Elan’s Tysabri Linked to First U.S. Case of Brain Infection
|
Luke Timmerman |
10/29/08 |
|
Boston
|
|
Allozyne Advances Toward Clinic, Sonosite Boots CFO, Leroy Hood’s Common Thread With Tupac, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/17/08 |
|
Seattle
|
|
Allozyne, Developer of Multiple Sclerosis Drug in Fewer Shots, Poised to Enter Clinical Trials
|
Luke Timmerman |
10/16/08 |
|
Seattle
|
|
Biogen Turns Down Dying Patient’s Request For Tysabri—and Explains Why
|
Luke Timmerman |
10/14/08 |
|
Boston
|
|
Leroy Hood, Turning 70, Still Aims to Accomplish “The Most Ambitious Things of My Career”
|
Luke Timmerman |
10/10/08 |
|
Seattle
|
|
Biogen Idec, Elan Start First Cancer Trial With Tysabri
|
Luke Timmerman |
09/05/08 |
|
Boston
|
|
ZymoGenetics Hands Over Atacicept Rights to Partner, Merck KGaA
|
Luke Timmerman |
09/03/08 |
|
Seattle
|
|
Biogen Idec Testing Regenerative Medicine Drug to Reverse the Path of Multiple Sclerosis
|
Luke Timmerman |
08/27/08 |
|
Boston
|
|
FDA Doesn’t Appear Overly Alarmed by Recent Cases of Brain Disease Associated With Tysabri; Working with Biogen Idec and Elan to Update Labeling
|
Luke Timmerman |
08/26/08 |
|
Boston
|
|
Taligen CEO Aims to Develop Drugs For Inflammatory Diseases, Build Company in Cambridge
|
Luke Timmerman |
08/14/08 |
|
Boston
|
|
Novo Nordisk Returning to Seattle, Hiring 80 People by 2010
|
Luke Timmerman |
08/05/08 |
|
Seattle
|
|
Biogen Idec, Elan Shares Plummet on News of Two PML Cases With Tysabri
|
Luke Timmerman |
08/01/08 |
|
Boston
|
|
Biogen Idec, Elan Report Two New Cases of Rare Brain Infection in Tysabri Patients
|
Luke Timmerman |
07/31/08 |
|
Boston
|
|
Biogen Idec, Elan Say More Than 31,800 Patients Taking Tysabri For MS
|
Luke Timmerman |
07/22/08 |
|
Boston
|
|
Biogen Idec Isn’t Sweating Possible Sale of Genentech to Roche
|
Luke Timmerman |
07/22/08 |
|
Boston
|
|
Genzyme Reaching For a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs
|
Luke Timmerman |
07/17/08 |
|
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2008 Xconomy. All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
